As such, PARP inhibition may be effective in blocking the ERK signaling network or increasing activity of ERK/MEK inhibitors, agents already shown to be efficacious in acute myeloid leukemia, multiple myeloma, melanoma, colorectal, breast, lung, and pancreatic cancers (64–68). This evidence concerns the gene MAPK1 and plasma cell myeloma.